Major Force in the Venous Thromboembolism Market 2025: Impact Of Healthcare Infrastructure Expansion On The Venous Thromboembolism Market

How Will the Venous Thromboembolism Market Grow, and What Is the Projected Market Size?
Over the past few years, the venous thromboembolism market has experienced a steady increase in its size. It's projected to expand from $2.44 billion in 2024 to $2.55 billion in 2025, rising at a compound annual growth rate (CAGR) of 4.4%. The growth during the historic period can be credited to an increasing elderly population, progress in anticoagulants, favorable reimbursement policies, and an increase in investments.

The market size of venous thromboembolism is predicted to experience consistent growth in the forthcoming years. The market is set to expand to $3.02 billion by 2029, registering a compound annual growth rate (CAGR) of 4.4%. The growth within the projected period can be attributed to factors such as enhanced access to global healthcare, genetic risk evaluation, telemedicine, and remote patient monitoring, in addition to patient education and support. Key trends projected for this period comprise extended thromboprophylaxis, innovative oral anticoagulants, individualized treatment plans, and high-tech diagnostic imaging technologies.

What Key Elements Are Boosting Growth in the Venous Thromboembolism Market?
The rise in healthcare facilities is predicted to fuel the growth of the venous thromboembolism market. The involvement and integration of sectors in the economic system that present products and services for curing, palliative care, rehabilitation and prevention of illnesses define the healthcare industry. The expansion of this industry aids the growth of institutional infrastructure, policies, practices and educational programs essential to support the execution of VTE prevention protocols. For example, as per the American Health Care Association, a nonprofit organization based in the US, the count of hospitals in the US surged to 6,129 from 6,093 in May 2023. Plus, according to the Office for National Statistics in the UK, spending on healthcare in the UK was roughly around £292 billion in 2023 showing a nominal rise of 5.6%. Spending on long-term health and social care also experienced an increase of 2.8% in real terms in 2022. Therefore, the enhancement in healthcare industry fosters the growth of the venous thromboembolism market. Advancement in the Venous Thromboembolism Market is expected due to the rising number of Orthopedic Procedures

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

Who Are the Major Industry Players Fueling Venous Thromboembolism Market Expansion?
Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

Which Key Developments Are Influencing the Venous Thromboembolism Market?
Leading companies within the venous thromboembolism market are focusing on the creation of innovative anticoagulant medications to maintain their strong market foothold. The progression of anticoagulant technology could result in increased efficacy in venous thromboembolism prevention or treatment. For example, Anthos Therapeutics, a clinical-stage biopharmaceutical firm based in the U.S., obtained regulatory approval in September 2022 for its abelacimab anticoagulant medication from the US Food and Drug Administration (FDA). This new treatment is a fully human monoclonal antibody, specifically designed to prevent stroke and systemic embolism in patients suffering from atrial fibrillation. The innovative, once-monthly, dual-acting antibody abelacimab aims to induce hemostasis-sparing anticoagulation by obstructing Factor XI.

How Is the Segmentation of the Venous Thromboembolism Market Defined?
The venous thromboembolism market covered in this report is segmented -

1) By Type: Deep Vein Thrombosis, Pulmonary Embolism, Other Types
2) By Treatment: Anti-Clotting Medications, Mechanical Devices, Thrombolytic Therapy, Other Treatment
3) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:
1) By Deep Vein Thrombosis (DVT): Proximal DVT, Distal DVT, Asymptomatic DVT
2) By Pulmonary Embolism (PE): Acute PE, Chronic PE, Submassive PE
3) By Other Types: Thrombophlebitis, Superficial Vein Thrombosis, Post-Thrombotic Syndrome

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

What Is the Leading Region in the Venous Thromboembolism Market?
North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Venous Thromboembolism Global Market Report?

- Market Size Analysis: Analyze the Venous Thromboembolism Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Venous Thromboembolism Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Venous Thromboembolism Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Venous Thromboembolism Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13001

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.